New Epilepsy Drug Cuts Seizures by 90% in UK Children

Freddie Truelove is skiing down mountains and walking his family's dogs around the lake, simple joys his parents once thought impossible.

The eight-year-old from Huddersfield suffered hundreds of seizures every day from Dravet syndrome, a devastating form of epilepsy affecting one in 15,000 babies. Now he's among the first UK children receiving a revolutionary new treatment that's changing everything.

The drug zorevunersen works differently than anything before it. Instead of just managing symptoms, it targets the root cause: a faulty gene that prevents the brain from making enough communication channels between neurons.

Doctors inject the medication into the lower spine, where it travels through spinal fluid to reach the brain. There, it helps ramp up production of the missing sodium channels that keep seizures at bay.

The results speak for themselves. Young patients in US and UK trials experienced up to 90% fewer seizures on repeat doses of the medication.

"We now have a life we didn't ever think was possible," Freddie's mum Lauren told BBC News. "Most importantly, it's a life that Freddie can enjoy."

Before treatment, Freddie's constant seizures kept him from normal childhood activities and put him at serious risk for injury or death. That's the harsh reality for families dealing with uncontrolled Dravet syndrome.

Now Freddie swims, skis, and explores the outdoors with his family. He's living proof that this experimental treatment offers real hope.

The Ripple Effect

Eighty-one children participated in the initial trials across hospitals in the UK and US, including Great Ormond Street, Sheffield Children's Hospital, and The Royal Hospital for Children in Glasgow. Nineteen of those young patients came from UK hospitals.

Professor Helen Cross from University College London's Institute of Child Health calls the results "amazing." She believes with the right treatment approach, children with Dravet syndrome could achieve near-normal lives long term.

The medication is still experimental and needs more years of research before doctors can widely recommend it. But for families who've watched their children suffer dozens or hundreds of daily seizures, the early promise feels like a miracle.

Galia Wilson, chair of trustees at Dravet Syndrome UK, says the organization regularly sees the devastating impact this condition has on families. She's thrilled about the trial results and looking forward to Phase Three clinical trials that will determine if this early promise translates into hope for all affected families.

Many trial participants, including Freddie, continue receiving the medication for ongoing research. Each dose brings researchers closer to understanding how to give these children their childhoods back.